Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

Sanofi is of­fload­ing its rare au­toim­mune dis­ease med­i­cine En­jay­mo to an Ital­ian phar­ma­ceu­ti­cal com­pa­ny for $825 mil­lion up­front.

Recor­dati, based in Mi­lan,

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER